FY2024 Earnings Forecast for ALDX Issued By Leerink Partnrs

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) – Equities researchers at Leerink Partnrs dropped their FY2024 earnings per share estimates for Aldeyra Therapeutics in a research note issued on Wednesday, November 13th. Leerink Partnrs analyst M. Goodman now forecasts that the biotechnology company will post earnings per share of ($0.95) for the year, down from their previous estimate of $0.70. The consensus estimate for Aldeyra Therapeutics’ current full-year earnings is ($0.89) per share. Leerink Partnrs also issued estimates for Aldeyra Therapeutics’ Q4 2024 earnings at ($0.28) EPS, FY2025 earnings at $2.00 EPS and FY2026 earnings at ($0.05) EPS.

Aldeyra Therapeutics (NASDAQ:ALDX) last issued its earnings results on Thursday, November 7th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.25).

Separately, HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Aldeyra Therapeutics in a report on Friday, August 9th.

Aldeyra Therapeutics Trading Up 11.6 %

Shares of ALDX stock opened at $4.70 on Monday. Aldeyra Therapeutics has a twelve month low of $2.43 and a twelve month high of $6.55. The company’s 50-day moving average price is $5.45 and its 200-day moving average price is $4.60. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.80 and a quick ratio of 6.80.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of ALDX. US Bancorp DE acquired a new stake in shares of Aldeyra Therapeutics during the third quarter valued at about $30,000. SG Americas Securities LLC purchased a new position in shares of Aldeyra Therapeutics during the 2nd quarter worth approximately $38,000. Paloma Partners Management Co acquired a new stake in Aldeyra Therapeutics in the 3rd quarter valued at approximately $62,000. Diversified Trust Co purchased a new stake in Aldeyra Therapeutics in the second quarter valued at approximately $41,000. Finally, King Wealth Management Group lifted its stake in Aldeyra Therapeutics by 24.5% during the third quarter. King Wealth Management Group now owns 13,700 shares of the biotechnology company’s stock worth $74,000 after purchasing an additional 2,700 shares in the last quarter. Institutional investors and hedge funds own 59.71% of the company’s stock.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-?B, inflammasomes, and Scavenger Receptor A.